China Orphan Drug Reimbursement: Swift Action Needed – Former Genzyme GM
This article was originally published in PharmAsia News
Executive Summary
Only 1% of 5,781 rare diseases in China have effective treatments. Facing reimbursement and infrastructure challenges, the market needs rapid action from government and industry, says Shirley Zhao, former Genzyme China general manager.